SCHEMBL4465669

SCHEMBL4465669

OC1c2ccccc2COc2ccccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.59
MAOB P27338 3/20 0.59
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44
HRH1 P35367 2/20 0.44
LTB4R Q15722 1/20 0.41
LTB4R2 Q9NPC1 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
CAMK2A Q9UQM7 1/20 0.40
HSD17B3 P37058 1/20 0.38
TERT O14746 1/20 0.37
GUSB P08236 1/20 0.37
NISCH Q9Y2I1 1/20 0.37
KMT2A Q03164 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11281780 0.83 MAOB (0.46) MAOAMAOBHTR2AHTR2CHRH1
SCHEMBL7464605 0.83 MAOA (0.64) MAOAMAOBLTB4RLTB4R2CYP1A2
SCHEMBL10728083 0.81 MAOB (0.42) MAOAMAOBHTR2AHTR2CHRH1
SCHEMBL7509154 0.81 KMT2A (0.42) MAOAMAOBHTR2AHTR2CHRH1
SCHEMBL7509159 0.81 TBXA2R (0.41) MAOAMAOBHTR2AHTR2CHRH1
SCHEMBL7510366 0.81 MAOA (0.43) MAOAMAOBHTR2AHTR2CCYP1A2
SCHEMBL9527650 0.81 NR3C2 (0.49) MAOAMAOB
SCHEMBL5400526 0.79 HTR2A (0.44) MAOAMAOBHTR2AHTR2CHRH1
SCHEMBL21996315 0.78 MAOB (0.40) MAOAMAOBHTR2AHTR2CHRH1
SCHEMBL10238629 0.78 HTR2A (0.47) MAOAMAOBHTR2AHTR2CHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220048897-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA INC (US) 2022-02-17 US disclosed
US-20200170254-A1 OXADIAZOLINE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISMS NIPPON SODA CO., LTD. (JP) 2020-06-04 US disclosed
US-20200170254-A1 OXADIAZOLINE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISMS NIPPON SODA CO., LTD. (JP) 2020-06-04 US disclosed
EP-3640244-A1 OXADIAZOLINE COMPOUND AND PEST CONTROL AGENT Nippon Soda Co., Ltd. (JP) 2020-04-22 EP disclosed
WO-2009137531-A2 COMPOSITIONS AND METHODS RELATED TO ACTION OF LOW DOSAGES OF DOXEPIN ON THE H1 AND 5-HT2A RECEPTORS SOMAXON PHARMACEUTICALS, INC. (US) 2009-11-12 WO disclosed
US-20040229899-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) JEPPESEN LONE (DK) 2004-11-18 US disclosed
US-6723731-B2 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY NOVO NORDISK A/S (DK) 2004-04-20 US disclosed
US-6602901-B2 Antidiabetic agents, obesity NOVO NORDISK A/S (DK) 2003-08-05 US disclosed
US-6525086-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2003-02-25 US disclosed
US-6407127-B2 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY NOVO NORDISK A/S (DK) 2002-06-18 US disclosed
US-5112817-A Anticancer Drug Potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-05-12 US disclosed
US-4999363-A Inhibit biosynthesis of thromboxane A2 KYOWA HAKKO KOGYO CO., LTD. (JP) 1991-03-12 US disclosed
EP-0363212-A2 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-04-11 EP disclosed
US-4889858-A ANTIHYPOXIC AGENTS, ANTICONVULSANTS, LIPID PEROXIDATION INHIBITORS DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1989-12-26 US disclosed
EP-0345747-A2 Tricyclic compounds KYOWA HAKKO KOGYO CO., LTD. (JP) 1989-12-13 EP disclosed
EP-0269755-A1 DIBENZ b,e OXEPIN DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME AS ACTIVE INGREDIENT Dainippon Pharmaceutical Co., Ltd. (JP) 1988-06-08 EP disclosed
EP-0069810-B1 NOVEL DIBENZOXEPINS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THE USE OF DIBENZOXEPINS IN THE TREATMENT OF ALLERGIC CONDITIONS MERCK & CO. INC. (US) 1986-12-03 EP disclosed
EP-0069810-A1 Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions MERCK & CO. INC. (US) 1983-01-19 EP disclosed
US-4282365-A Dibenz[b,e]oxepin compounds MERCK & CO., INC. (US) 1981-08-04 US disclosed
US-4169205-A BACTERICIDES; FUNGICIDES E. R. SQUIBB & SONS, INC. (US) 1979-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048897-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION ACE, IRF3, MIF MAOA 230/4885MAOB 154/4885HTR2A 4522/4885
US-20200170254-A1 OXADIAZOLINE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISMS OXA1L, O60361, FOXO3 MAOA 2356/4885MAOB 764/4885HTR2A 3337/4885
US-20040229899-A1 Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) PPARG, PPARA, PPARD MAOA 1821/4885MAOB 1574/4885HTR2A 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.